



PATENT
ATTORNEY DOCKET NO. 47234.0003/00US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Naoyuki TANIGUCHI et al.) Confirmation No.: 7031
Application No.: 10/500,841) Group Art Unit: 1652
Filed: February 15, 2005) Examiner: Igbal Hossain Chowdhury, Ph.D.
For: GLYCOSYLTRANSFERASE GNT-V HAVING NEOVASCULARIZATION
ACTION (As Amended)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window Mail Stop: Amendment AF Issue Fee
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT (IDS)

Under 37 C.F.R. § 1.97(b): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. To the undersigned's knowledge, this IDS is being filed before the mailing date of a first Office Action on the merits, before the mailing date of a first Office Action on the merits after filing an RCE under § 1.114, or within three months of the application filing date.

A search report or other listing of documents from a counterpart, related, or other application dated September 5, 2005 and having documents cited thereon is attached for the Examiner's consideration. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.

Under 37 C.F.R. § 1.97(c): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Office Action, a Notice of Allowance, or another action that closes prosecution in the application.

The fee of \$180.00 set forth in § 1.17(p) is included herein; or

Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

Under 37 C.F.R. § 1.97(d): Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(c) but before payment of the issue fee.

- The fee of \$180.00 set forth in § 1.17(p) is included herein; and
- Applicant submits that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- Under 37 C.F.R. § 1.97(i):** Pursuant to 37 C.F.R. §§ 1.56 and 1.97(i), Applicant brings to the attention of the Examiner the documents listed on the attached PTO Form 1449. This IDS is being filed after the events recited in § 1.97(d). Applicant requests that the IDS be placed in the file.
- The fee of \$180.00 set forth in § 1.17(p) is included herein.
- A search report or other listing of documents from a counterpart, related, or other application dated _____ and having documents cited thereon is attached for the Examiner's consideration. Any of these documents not previously cited, and any additional documents are listed on the PTO Form 1449.
- Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. As for any document listed on the accompanying PTO-1449 that is in a language other than English, relevance can be understood from an enclosed English abstract or at least partial translation or from mention in the specification or in a search report for a corresponding application.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that any of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should any of the documents be applied against the claims of the present application.


Respectfully submitted,

DRINKER, BIDDLE & REATH LLP

Dated: March 16, 2006


Mercedes K. Meyer, Ph.D., Esq.
Registration No. 44,939

CUSTOMER NO. 055694
DRINKER, BIDDLE & REATH LLP
1500 K Street, N.W., Suite 1100
Washington, D.C. 20005-1209
Tel: 202.842.8800; Fax: 202.842.8465



<div style="text-align: center;">  U.S. Department of Commerce Date Filed: <u>February 2, 2006</u> </div>				DOCKET NO. 034100-0003		APPLN. NO. 10/500,841	
				APPLICANT: Naoyuki TANIGUCHI et al.			
				FILING DATE: February 15, 2005		GROUP: 1652	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes/No/Abstract
		10-137000	26MAY1998	Japan	C12N		Abstract
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, etc.)							
		Taniguchi, Naoyuki et al., "Implication of GnT-V in Cancer Metastasis: A Glycomic Approach for Identification of a Target Protein and Its Unique Function as an Angiogenic Cofactor," <i>Glycoconjugate Journal</i> Nov-Dec, Vol. 18, Nos. 11-12, November 2001, pp. 859-865.					
		Daniel, Paris et al., "Inhibition of Angiogenesis and Tumor Growth by Beta and Gamma-Secretase Inhibitors," <i>European Journal of Pharmacology</i> 514(1): 1-15, May 2005.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).
PTO-1449.doc